FDA OKs Dupilumab for Moderate-to-Severe Eczema in Teens FDA OKs Dupilumab for Moderate-to-Severe Eczema in Teens

The"breakthrough" therapy is for adolescents as young as 12 with moderate-to-severe atopic dermatitis poorly controlled with other therapies, or when those therapies are contraindicated.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Alert Source Type: news